{"id":"NCT01656759","sponsor":"Rush University Medical Center","briefTitle":"Use of a Novel Fibrin Sealant in Total Knee Arthroplasty","officialTitle":"Use of a Novel Fibrin Sealant in Total Knee Arthroplasty: A Prospective Randomized Controlled Clinical Trial","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-05","primaryCompletion":"2014-12","completion":"2015-08","firstPosted":"2012-08-03","resultsPosted":"2016-02-09","lastUpdate":"2016-02-09"},"enrollment":73,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis","Intraoperative Bleeding"],"interventions":[{"type":"DRUG","name":"Evicel Fibrin Spray","otherNames":["Produced by OMRIX Biopharmaceuticals, Ltd."]}],"arms":[{"label":"Control Group","type":"NO_INTERVENTION"},{"label":"Treatment Group--Evicel Fibrin Spray","type":"ACTIVE_COMPARATOR"}],"summary":"Applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased blood loss there should be a reduced need for blood transfusions.","primaryOutcome":{"measure":"Primary--Percent Change of Pre- to Post-Operative Hemoglobin","timeFrame":"Pre-operative to 1 month","effectByArm":[{"arm":"Control Group","deltaMin":20.1,"sd":7},{"arm":"Treatment Group--Evicel Fibrin Spray","deltaMin":22.5,"sd":5.7}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["10565650","11679600"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Superficial Wound Dehiscence"]}}